Malignant tumor of nasopharynx

Summary

Malignant tumor of nasopharynx (MONDO:0021315) is a cancer and 12 clinical trials. Top therapeutic interventions include cetuximab, interferon beta-1a, and buparlisib. A subtype of nasopharyngeal neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 12

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	malignant tumor of nasopharynx
Mondo ID	MONDO:0021315
ICD-10-CM	C11
NCIT	C9321
SNOMED CT	187692001
UMLS	C0153392
MedGen	56299
Anatomy (UBERON)	UBERON:0001728
Is cancer (heuristic)	yes

Also known as: cancer of nasopharynx · malignant nasopharyngeal neoplasm · malignant nasopharyngeal tumor · malignant nasopharyngeal tumour · malignant nasopharynx neoplasm · malignant neoplasm of nasopharynx · malignant neoplasm of the nasopharynx · malignant tumor of the nasopharynx · malignant tumour of the nasopharynx · nasopharynx cancer

Disease family

This is a subtype of nasopharyngeal neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › upper respiratory tract disorder › nasopharyngeal disorder › nasopharyngeal neoplasm › malignant tumor of nasopharynx

Related subtypes (2): nasopharyngeal teratoma, benign neoplasm of nasopharynx

Subtypes (1): nasopharyngeal carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 12.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	5
Not specified	4
PHASE1	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02948699	PHASE4	UNKNOWN	A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients
NCT06019130	PHASE2	RECRUITING	Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
NCT06611826	PHASE2	NOT_YET_RECRUITING	GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC
NCT03082534	PHASE2	COMPLETED	Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
NCT03096808	PHASE2	COMPLETED	Adaptive Radiotherapy for Head and Neck Cancer
NCT04004871	PHASE2	COMPLETED	Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma
NCT06614686	PHASE1	RECRUITING	U87 CAR-T in Patients With Advanced Head and Neck Tumors
NCT02113878	PHASE1	COMPLETED	Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
NCT05483374	Not specified	RECRUITING	The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers
NCT00797290	Not specified	TERMINATED	Photon/Proton Radiation Therapy for Carcinoma of the Nasopharynx
NCT03448341	Not specified	COMPLETED	Dysphagia Assessment After Swallowing Sparing RadioTherapy
NCT03791944	Not specified	COMPLETED	3DV+TPS Applied to Radiotherapy for Nasopharyngeal Carcinoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CETUXIMAB	4	1
INTERFERON BETA-1A	4	1
BUPARLISIB	3	1